John Libbey Eurotext

European Journal of Dermatology


Journal Club: Recent therapeutic developments in trichology Volume 32, numéro 3, May-June 2022

1 Department of Dermatology. Hospital General Universitario Gregorio Marañón, Madrid, Spain
2 CIRI, Centre International de Recherche en Infectiologie, (Team Immunology of Skin Allergy and Vaccination); INSERM, U1111; Univ Lyon; Université de Lyon 1; Ecole Normale Supérieure de Lyon; CNRS, UMR5308, Lyon, France. Department of Dermatology and Allergology, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Priest-en-Jarez, France
3 Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
4 Dermatology Department, Cambridge University Hospitals, Addenbrookes Hospital, Cambridge, UK
5 Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
6 Department of Dermatology, Hospital Universitario Puerta de Hierro, Madrid, Spain

Androgenetic alopecia (AGA) or male-pattern baldness affects more than half of men below 50 years of age [1], frequently at the vertex of the scalp [2], with great impact on their quality of life [3]. Due to the action of type II 5α-reductase [1], this genetically determined disorder implies a higher rate of conversion of testosterone to dihydrotestosterone (DHT) within the hair follicle, which results in its miniaturization. Common AGA treatments include oral finasteride, topical minoxidil (a pyrimidine [...]